Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants
July 29 2021 - 8:00AM
Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the
“Company”) announces that its SARS-CoV-2 3CL protease lead
CDI-45205 and several analogs showed potent in vitro activity
against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma
(Brazil/P.1) variants. Cocrystal previously announced that
CDI-45205 and analogs exhibited broad-spectrum activity against the
SARS-CoV-2 Alpha (United Kingdom/B.1.1.7) and Beta (South
African/B.1.351) variants, surpassing the activity observed with
the Wuhan strain.
“These in vitro SARS-CoV-2 results further
indicate that Cocrystal’s SARS-CoV-2 3CL protease inhibitor
CDI-45205 may be an effective treatment for COVID-19 caused by
SARS-CoV-2 and its emerging variants, including the fast-spreading
Delta variant that is becoming the dominant COVID-19 variant
globally,” said Sam Lee, Ph.D., Cocrystal’s President and interim
co-CEO. “The broad-spectrum activity against these SARS-CoV-2
variants is highly encouraging as CDI-45205 previously demonstrated
excellent in vivo efficacy in a MERS-CoV-2 infected animal
model.”
“CDI-45205 has now shown antiviral activity in
preclinical testing against SARS-CoV-2 and all four major
variants,” said James Martin, CFO and interim co-CEO, “Our next
steps are to scale-up synthesis and manufacture active
pharmaceutical ingredient (API) to support Investigational New Drug
(IND)-enabling studies to advance CDI-45205 into clinical
trials.”
The Company continues to develop SARS-CoV-2 oral
protease inhibitors and replication inhibitors using its
proprietary drug discovery platform technology. Cocrystal’s
approach to drug discovery provides a unique path for designing
broad-spectrum coronavirus antivirals against SARS-CoV-2 and
emerging variants.
About
CDI-45205 Cocrystal announced agreements in
February and April 2020 with Kansas State University Research
Foundation (KSURF) for certain proprietary broad-spectrum CL3
antiviral compounds for the treatment of norovirus and coronavirus
infections. In December 2020 Cocrystal announced the selection of
CDI-45205 as its lead coronavirus development candidate from a
group of protease inhibitors obtained under the KSURF agreements.
CDI-45205 showed good bioavailability in mouse and rat
pharmacokinetic studies via intraperitoneal injection, and also no
cytotoxicity against a variety of human cell lines. CDI-45205 has
also demonstrated a strong synergistic effect with remdesivir.
Additionally, a proof-of-concept animal study demonstrated that
daily injection of CDI-45205 exhibited favorable in vivo efficacy
in MERS-CoV-infected mice. Cocrystal has obtained promising
preliminary pharmacokinetic results and is continuing to evaluate
CDI-45205.
About Cocrystal Pharma,
Inc.Cocrystal Pharma, Inc. is a clinical-stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of coronaviruses
(including SARS-CoV-2), influenza viruses, hepatitis C virus and
noroviruses. Cocrystal employs unique structure-based technologies
and Nobel Prize-winning expertise to create first- and
best-in-class antiviral drugs. For further information about
Cocrystal, please visit www.cocrystalpharma.com.
Cautionary Note Regarding
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding our beliefs related to the effectiveness of CDI-45205
against SARS-CoV-2 and its major variants, and the anticipated
clinical development of CDI-45205. The words "believe," "may,"
"estimate," "continue," "anticipate," "intend," "should," "plan,"
"could," "target," "potential," "is likely," "will," "expect" and
similar expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements largely on our current expectations and projections
about future events. Some or all of the events anticipated by these
forward-looking statements may not occur. Important factors that
could cause actual results to differ from those in the
forward-looking statements include, but are not limited to, the
risks and uncertainties arising from the impact of the COVID-19
pandemic on the national and global economy and on our Company,
including supply chain disruptions and our continued ability to
proceed with our programs, including our coronavirus program, our
ability to complete the preclinical and clinical trials of
CDI-45205, the results of such future preclinical and clinical
studies, and general risks arising from clinical trials and more
generally, the development of investigational drugs. Further
information on our risk factors is contained in our filings with
the SEC, including our Annual Report on Form 10-K for the year
ended December 31, 2020. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Investor Contact:LHA Investor
RelationsJody Cain310-691-7100jcain@lhai.com
# # #
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024